Cutaneous T-Cell Lymphoma Therapy: From Topicals to CAR-T in 2026

Introduction: Understanding the Modern CTCL Treatment Journey

Cutaneous T-cell lymphoma (CTCL) is rarely managed with a single, decisive treatment. For most patients, it is a chronic condition. Treatment happens in stages over many years, with one therapy often followed by another as the disease responds, stabilizes, or returns.

Patients and caregivers searching for information usually find two kinds of resources. Basic overviews explain what CTCL is but say little about the newest therapies. Pipeline reports and journal articles cover the latest science in language written for clinicians and investors. This guide connects the two.

This guide follows the order in which treatment is usually offered. It begins with skin-directed therapy, moves through systemic agents and the most recent FDA approval, and ends with emerging cellular immunotherapies such as CAR-T. Throughout, it explains how subtype (mycosis fungoides versus Sézary syndrome) and stage shape each decision.

This guide is educational. It does not replace evaluation and care at a specialized CTCL center.

What Is Cutaneous T-Cell Lymphoma? A Quick Foundation

CTCL is a group of non-Hodgkin lymphomas that begin in malignant T-cells, a type of white blood cell. These cells tend to “home” to the skin, which is why the disease first appears there. The two most common subtypes behave quite differently:

• Mycosis fungoides (MF): Usually slow-growing. It often begins as patches or plaques on the skin that can resemble eczema or psoriasis.
• Sézary syndrome (SS): A more aggressive form. It involves widespread skin redness (erythroderma) and malignant T-cells circulating in the blood.

Key epidemiology:

• A JAMA Oncology analysis of US SEER data covering 2000 to 2018 found an overall incidence of 8.55 cases per million people, and the rate rose over that period.
• Other estimates put incidence closer to 12.4 per million annually.
• CTCL accounts for about 4% of all non-Hodgkin lymphoma cases.
• Sézary syndrome showed the steepest rise in incidence, with an annual percent change of 3.83%. Mycosis fungoides also rose faster than CTCL overall.
• Research also points to rising rates among US children and young adults.
• Men are affected about twice as often as women, and diagnosis typically occurs between ages 55 and 65.

Prognosis depends heavily on stage. Stage IA mycosis fungoides carries a median survival of 35.5 years, with 90% disease-specific survival at 20 years. Advanced Sézary syndrome, by contrast, has roughly a 10% five-year overall survival rate. Because outcomes range so widely, the choice and order of treatments matter a great deal.

How Treatment Decisions Are Made: Staging and Subtype Matter

The major guideline bodies all base treatment on stage rather than a single universal protocol. These include the National Comprehensive Cancer Network (NCCN), the European Organisation for Research and Treatment of Cancer (EORTC), and the European Society for Medical Oncology (ESMO). NCCN also recommends that patients with MF or SS be treated at specialized centers with CTCL-specific expertise.

Broadly, treatment falls into two categories:

• Early-stage disease (stages IA to IIA): Usually managed with skin-directed therapies.
• Advanced or systemic disease (stage IIB and higher, including Sézary syndrome): Requires systemic treatment or combination approaches.

MF and SS are related, but they often follow different treatment pathways and frequently have different eligibility criteria for clinical trials.

Specialists describe treatment in terms of “lines of therapy.” A first-line treatment is what a patient receives first. Second-line and later treatments follow if the disease progresses or stops responding. Stage matters, but so does a patient’s history of prior treatments. Many newer drugs are approved only for patients who have already tried at least one systemic therapy.

Step One: Skin-Directed Therapies for Early-Stage Disease

For early-stage disease, treatment starts at the skin. Common first-line options include:

• Topical corticosteroids to reduce inflammation and clear patches.
• Mechlorethamine (nitrogen mustard) gel, a topical chemotherapy applied directly to lesions.
• Topical carmustine, another skin-applied chemotherapy agent.
• Imiquimod, an immune-response modifier used on limited lesions.
• Phototherapy, including PUVA (psoralen plus UVA light) and narrowband UVB.
• Localized radiation therapy for stubborn or thicker lesions.

These therapies come first for three reasons. They cause less systemic toxicity. They work well when disease is limited to the skin. And they are consistent with the favorable long-term outlook of stage IA and IB disease.

Many patients move through several skin-directed therapies over time, transitioning to systemic treatment only when the disease progresses.

Step Two: Moving to Systemic Therapy as Disease Advances

Systemic therapy becomes necessary when CTCL extends beyond the skin. Common triggers include involvement of the lymph nodes, blood, or internal organs, or a diagnosis of Sézary syndrome.

Extracorporeal photopheresis (ECP) is a key option, especially for Sézary syndrome and disease involving the blood. In ECP, the patient’s blood is drawn and treated with a light-sensitizing agent and UV light, then returned to the body. This process is thought to stimulate an immune response against the malignant cells.

Retinoids and Immune-Modulating Agents

Bexarotene and other retinoids are oral systemic options. They act on retinoid receptors inside cells, which helps regulate how malignant T-cells grow and die.

Interferons are an older immune-modulating therapy that remains in use. They help strengthen the body’s own immune activity against the lymphoma.

In practice, these agents are often combined with skin-directed therapy rather than used alone. A patient might take bexarotene while continuing phototherapy, for example.

HDAC Inhibitors: Vorinostat and Romidepsin

Histone deacetylase (HDAC) inhibitors work through epigenetics, which refers to how genes are switched on or off. These drugs change which genes are active in malignant cells, which can slow their growth or trigger their death.

Vorinostat and romidepsin are typically used for relapsed or refractory disease, often after retinoids or other systemic agents. Patients should ask their care team about monitoring requirements (such as blood counts and heart rhythm checks), side effects, and realistic expectations for how quickly a response might appear.

Targeted Antibody Therapies: Mogamulizumab and Brentuximab Vedotin

• Mogamulizumab is a monoclonal antibody that targets CCR4, a protein commonly found on malignant CTCL cells. It is particularly relevant for Sézary syndrome and disease involving the blood.
• Brentuximab vedotin is an antibody-drug conjugate. It targets CD30 and delivers a toxic payload directly to cells that carry this marker. It is used specifically for CD30-positive CTCL.

These drugs are early examples of biomarker-driven, precision-matched therapy in CTCL: a specific marker on the cancer cell determines whether a treatment is likely to work. They also mark a shift away from broad chemotherapy toward targeted systemic treatment. The same logic reappears later with the KIR3DL2 target and lacutamab.

The Newest FDA Approval: Denileukin Diftitox-cxdl (Lymphir)

In August 2024, the FDA approved denileukin diftitox-cxdl (Lymphir) for adults with relapsed or refractory stage I to III CTCL who have received at least one prior systemic therapy.

How it works: The drug is a fusion toxin. It combines part of interleukin-2 (IL-2), a natural immune signaling protein, with a toxin. The IL-2 portion guides the drug to cells that carry the IL-2 receptor, including malignant T-cells, and the toxin kills those cells.

Pivotal results: In Study 302, published in the Journal of Clinical Oncology, the objective response rate was 36.2% as assessed by an independent review committee. Median duration of response ranged from 6.5 to 8.9 months, depending on the assessment method.

The boxed warning: The drug carries an FDA boxed warning for capillary leak syndrome. In this condition, fluid leaks from small blood vessels into surrounding tissues. Patients and caregivers should watch for:

• Sudden weight gain
• New or worsening swelling, especially in the legs or around the eyes
• Low blood pressure, dizziness, or shortness of breath

Any of these should be reported to the care team promptly.

For patients who have already worked through earlier systemic options, this approval adds one more tool to the treatment sequence.

Why CAR-T Has Lagged in CTCL Compared to B-Cell Lymphomas

CAR-T therapy has transformed the treatment of certain B-cell lymphomas. In this approach, a patient’s immune cells are engineered to recognize and destroy cancer. Many patients hear about these successes and reasonably ask whether CAR-T is available for CTCL.

Progress in T-cell lymphomas has been much slower, for biological reasons that are rarely explained in patient materials. The sections below describe those reasons in plain language.

The Fratricide Problem

CAR-T cells are themselves T-cells. When they are engineered to attack a marker found on malignant T-cells, such as CD4, CD5, or CD7, they may also attack each other, because they carry many of the same markers. This self-destruction is called fratricide.

An analogy helps. Imagine training security guards to arrest anyone wearing a blue uniform, while the guards themselves wear blue. They end up arresting each other before they can find the intruders.

B-cell lymphoma CAR-T avoids this problem. Those therapies target CD19, a marker found on B-cells but not on the T-cells used to make the CAR-T product. The engineered cells do not attack themselves.

Shared Antigens and Healthy T-Cell Depletion

Targets like CD4, CD5, and CD7 appear on healthy T-cells as well as malignant ones. In B-cell disease, patients can live with the loss of CD19- or CD20-positive B-cells with manageable support. Losing large numbers of T-cells is far more dangerous.

The result can be T-cell aplasia, a severe depletion of T-cells that weakens the immune system broadly and leaves patients vulnerable to serious infections.

There is also a manufacturing contamination risk. Autologous CAR-T products are made from a patient’s own T-cells. In CTCL, and especially in Sézary syndrome, malignant T-cells circulate in the blood. They can be collected by accident and end up in the final product.

Autologous vs. Allogeneic Strategies: Two Paths Forward

• Autologous CAR-T uses the patient’s own cells. In CTCL it faces both the contamination and fratricide challenges described above.
• Allogeneic CAR-T uses cells from healthy donors. This approach is designed to avoid contamination with cancerous T-cells, and gene editing can help reduce fratricide.

Tumor heterogeneity adds another complication. Malignant cells in CTCL do not all carry the same markers, so a therapy aimed at a single target may miss some cancer cells. Researchers are testing new targets and cell platforms to address these challenges.

The Emerging Cellular and Targeted Immunotherapy Pipeline, Translated

Industry pipeline reports list dozens of companies and investigational therapies in dense technical language. This section translates the most notable developments.

A systematic review of 134 CTCL clinical trials conducted between 2020 and 2025 was published in April 2026. It found therapies spanning:

• Antibody and biologic agents (31 trials)
• Immunotherapy (26)
• Signaling pathway inhibitors (21)
• Epigenetic modifiers (20)
• Skin-directed modalities (16)
• Apoptosis modulators and protein degraders (10)
• Cellular therapies (10)

The spread shows how quickly the field is diversifying.

CTX130 and Allogeneic CAR-T: CD70 as a New Target

CTX130, developed by CRISPR Therapeutics, is an allogeneic CAR-T therapy made from healthy donor cells and edited with CRISPR-Cas9. It targets CD70, a marker found on many malignant T-cells.

In the Phase 1 COBALT-LYM trial, published in The Lancet Oncology, researchers treated patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and CTCL. Among 39 heavily pretreated patients, 18 had objective responses.

On safety:

• Cytokine release syndrome (CRS) occurred in 67% of patients. CRS is an inflammatory reaction triggered when activated immune cells release large amounts of signaling proteins. It can cause fever, low blood pressure, and fatigue, and it is a known, generally manageable effect of CAR-T therapy.
• Low-grade neurotoxicity, such as confusion or headache, occurred in 10%.

A next-generation candidate, CTX131, is in development, reflecting ongoing refinement of the approach.

Lacutamab and the KIR3DL2 Target: Precision Medicine for Sézary Syndrome

Lacutamab is an antibody, not a cell therapy. It is part of the same biomarker-driven movement and targets KIR3DL2, a receptor expressed on roughly 65% of CTCL patients across subtypes and up to 90% of Sézary syndrome patients. Because the marker is so common in SS and relatively uncommon on healthy cells, it is a promising target.

Key milestones:

• February 2025: The FDA granted lacutamab Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome.
• Phase 2 TELLOMAK trial: Global objective response rate of 42.9% in Sézary syndrome and 19.6% in mycosis fungoides.
• Phase 3 TELLOMAK 3: The FDA cleared this confirmatory trial, which began enrolling in the first half of 2026. It compares lacutamab with romidepsin or mogamulizumab and could support accelerated approval.

For patients, this means lacutamab is not yet commercially available. Access currently comes through clinical trials, and wider availability depends on regulatory review in the years ahead.

CAR-NK Cells and Other Cellular Strategies on the Horizon

CAR-NK therapy uses natural killer (NK) cells instead of T-cells. NK cells are a different part of the immune system, and many lack the T-cell markers that cause fratricide. This could sidestep some of CAR-T’s CTCL-specific problems.

These approaches remain earlier-stage and investigational compared with CAR-T and antibodies like lacutamab. The recent systematic review identified 10 cellular therapy trials, which shows that researchers are pursuing several mechanisms rather than relying on a single one.

Allogeneic Stem Cell Transplant: A Potentially Curative Option

Allogeneic hematopoietic stem cell transplantation (HSCT) differs from the targeted and cellular therapies above. It replaces the patient’s blood-forming system with donor cells, and the donor’s immune cells can recognize and eliminate lymphoma cells over the long term.

Nonmyeloablative (reduced-intensity) allogeneic transplant has achieved clinical and molecular remission in some CTCL patients. HSCT is typically reserved for advanced or refractory disease. It carries significant risks, including graft-versus-host disease and serious infection. Eligibility depends on overall health, disease status, and donor availability, and it is best evaluated at a specialized transplant and CTCL center.

Weighing Standard of Care Against Clinical Trials

Patients often have to decide between enrolling in a clinical trial, such as a lacutamab or allogeneic CAR-T study, and continuing standard sequential therapy. Relevant factors include:

• Current disease status and how well existing therapies are working
• Subtype and biomarkers, such as KIR3DL2 or CD30 expression
• Prior lines of therapy. Eligibility for denileukin diftitox-cxdl and for lacutamab trials often requires a specific treatment history.
• Practical considerations, including travel, visit frequency, and caregiver support

Experts note that advanced CTCL and Sézary syndrome have historically shown modest response rates to systemic therapy, without a demonstrated overall survival benefit. This is why trials of new mechanisms are so important. A CTCL specialist can help match patients to relevant trials. Consistent with NCCN guidance, specialized centers generally offer the widest range of options.

Living With CTCL: Quality of Life and Caregiver Considerations

A disease that improves and then relapses over many years takes an emotional and practical toll. Visible skin symptoms, persistent itching, repeated appointments, and uncertainty can affect mood, sleep, work, and relationships.

Multidisciplinary support makes a meaningful difference. Care teams often include dermatology, oncology, and nursing, with access to mental health professionals and support groups.

NCCN describes CTCL as “treatable, but generally not curable.” Seen this way, the goal shifts from one decisive cure to long-term control, symptom relief, and quality of life. Many patients, particularly those with early-stage MF, live for decades with well-managed disease.

Caregivers can help by keeping organized records of past treatments and responses and by staying informed about emerging options. They should also keep realistic expectations about when investigational therapies might become broadly available.

Conclusion: A Rapidly Evolving, Increasingly Personalized Treatment Landscape

The CTCL treatment journey follows a clear sequence. Skin-directed therapy remains the foundation for early-stage disease. Systemic agents, from retinoids and HDAC inhibitors to targeted antibodies, extend options as disease advances. Newer approvals such as denileukin diftitox-cxdl add tools for relapsed and refractory patients.

Cellular immunotherapy (CAR-T and CAR-NK) and precision antibodies such as lacutamab represent the next frontier. Their biological challenges, including fratricide, shared antigens, and product contamination, are being addressed through allogeneic strategies and new targets such as CD70 and KIR3DL2.

Because CTCL is chronic and varies widely between patients, decisions about which treatment to use and when are best made with specialist guidance. There is reason for measured optimism: response rates and treatment options have expanded meaningfully in just the past two years, even though a definitive cure remains elusive for advanced disease.

Next Steps: Talk to a Specialist About Your CTCL Treatment Options

Patients and caregivers can bring this guide’s framework of staging, sequencing, and emerging options into conversations with their dermatology or oncology team. Useful questions include:

• What is my exact subtype and stage, and how does that affect my options?
• Which line of therapy am I on now, and what typically comes next?
• Has my disease been tested for markers such as CD30 or KIR3DL2?
• Am I a candidate for clinical trials involving lacutamab, allogeneic CAR-T, or other new agents?
• Should I be evaluated at a specialized CTCL center or for stem cell transplant?

Readers who want to learn more can explore additional educational resources, including those available through adiamed.com. Connecting with specialized CTCL care is the most reliable way to build a personalized treatment plan.